
Core Viewpoint - TransCode Therapeutics has announced a 1-for-28 reverse stock split to comply with Nasdaq's minimum bid price requirements, aiming to increase the trading price of its common stock [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert twenty-eight current shares into one new share, reducing the total outstanding shares from approximately 23,341,336 to about 833,620 [2]. - No fractional shares will be issued; instead, stockholders will receive rounding up of fractional shares to the nearest whole number [2]. - Proportional adjustments will be made to the exercise prices of outstanding stock options and warrants, as well as to the shares issued under stock incentive plans [2]. Group 2: Implementation and Process - Vstock Transfer LLC will serve as the exchange agent for the reverse stock split, and stockholders of record will not need to take action to receive their post-split shares [3]. - Stockholders holding shares through banks or brokers will have their positions automatically adjusted, but they may need to check with their respective institutions for specific procedures [3]. - The effective date of the reverse stock split will be announced by the company at least two business days prior to implementation [4]. Group 3: Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics [5]. - The company's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5]. - TransCode is also developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5].